MedImmune Loss Widens on Charges, R&D
455095
MedImmune Inc. MEDI.O, maker of the  nasal spray flu vaccine FluMist, on Thursday said its  third-quarter loss widened on higher costs and one-time  charges.
690369
Communications equipment network maker 3Com Corp  on Thursday posted a wider net loss from a year ago, partly due to higher research and development costs.
12588
The health insurer beats some estimates and raises others.
266289
Pushing more of the cost of prescription drugs onto consumers causes patients to cut back, sometimes with adverse health consequences, according to a review of two decades worth of studies published on Tuesday.
129481
MedImmune Inc. will provide an additional 1 million doses of its FluMist nasal-spray vaccine this year to help the country overcome a shortage of flu shots, US health officials said yesterday.
672696
Although government officials asked MedImmune to help with the flu vaccine shortage, the maker of a nasal anti-flu spray will lose money on every dose it sells.
478185
With complicated and costly "biologics"  increasingly seen as the wave of the pharmaceutical future, health care experts warn that they will drive the nation's fast-growing bill for drugs far higher.
633082
Bristol-Myers Squibb Co on Thursday  reported a loss from continuing operations as special charges  more than offset strong sales growth of its array of  prescription drugs.
524078
Patients with a potentially fatal lung condition have spent hundreds of millions of dollars on a drug that was not approved for their disease but was promoted for that use.
163351
MedImmune's shares sank nearly 9 percent yesterday after the company reported weaker-than-expected fourth-quarter revenue for two high-profile products and disclosed a delay in filing for federal approval of a new version of Synagis, its lead drug.
54609
SEC upgrades investigation into vaccine manufacturer.
144403
US health officials Thursday said MedImmune Inc. has made available an additional 1 million doses of its FluMist nasal spray flu vaccine.
625984
Merck and Co  on Wednesday reported a fourth-quarter loss due to charges from a costly settlement related to its withdrawn Vioxx arthritis drug, but results soundly beat Wall Street forecasts and lifted its shares 2 percent.
621950
The drugstore chain said its quarterly loss narrowed as a result of an income tax benefit and increased sales of generic drugs.
425170
Faced with weak development pipelines that are putting a drag on stock prices, drug manufacturers are retooling the decades-old system of clinical trials to make it faster and cheaper.
138376
The ballooning cost of cancer treatment offers an example of how difficult it may be to rein in the nationâs runaway health care spending.
249444
U.S. prescription drug sales rose 8.3 percent to $274 billion last year, fueled by the Medicare drug benefit, increased use of generic medicines and new treatments for diseases such as cancer and diabetes, according to a new report.